To overview
6-Month Report
Carl Zeiss Meditec continues its profitable growth in first six months of financial year 2011/2012 Downloads and Links

Revenue 14.8 percent higher than previous year – EBIT margin grows to 14.1 percentRTF Documents
english (7894 KB)

Further Information
Deutsche Version

JENA/Germany, 15.05.2012.
Medical technology provider Carl Zeiss Meditec generated growth of 14.8 percent in the first six months of financial year 2011/2012. The company posted revenue of EUR 431.8 million – EUR 56 million more than for the same period of the previous year (EUR 376.0 million). Once again, Carl Zeiss Meditec AG improved its profitability, increasing its earnings before interest and tax (EBIT) by 19 percent to EUR 61.1 million (previous year: EUR 51.3 million). The EBIT margin increased to 14.1 percent (previous year: 13.6 percent).

"I am particularly delighted that we achieved very profitable growth," says Dr. Ludwin Monz, Presi- dent and CEO of Carl Zeiss Meditec AG. “The half-year result is an endorsement of our strategy to strengthen our broad business portfolio with innovations and to grow on a global scale."

Key figures at a glance

The largest contribution to total revenue came from the Microsurgery business unit, with growth of 23.9 percent. This increase in revenue is due in particular to the new products launched last year. Radiation therapy sales also showed continuing growth.

The Surgical Ophthalmology business unit benefited from the strong demand for intraocular lenses for minimally invasive cataract surgery. This strategic business unit (SBU) grew by 14.8 percent.

The Ophthalmic Systems SBU grew by 6.6 percent. In particular the new ReLEx® smile procedure for refractive laser surgery, launched in 2011, contributed to this growth.

In terms of the reporting regions, the stable trend in the Asia/Pacific region continued with growth of 13.3 percent. This region continues to hold the greatest growth potential. A perceptible recovery in Europe and America also led to encouraging growth in these two regions. "Nevertheless, this was an unusual quarter characterized by backlog effects," explains Monz. Revenue in the EMEA region grew by 14.9 percent. Both the consoli- dation of the business operations acquired from IMEX in Spain and the strong demand in Eastern Europe are continuing to have a positive effect. Revenue in the Americas region increased by 16.2 percent. The US continued to perform well, while South America once again achieved double-digit growth.

Confident about the future

Carl Zeiss Meditec is forecasting further growth in the second half of the current financial year, assuming that the economic climate continues to stabilize. However, this growth will not be quite as significant as in the first six months, partly for seasonal reasons.

"Our revenue target for financial year 2011/2012 as a whole is EUR 830 to EUR 860 million. This would mean year-on-year growth of between 9.4 and 13.3 percent," says Monz. "We are adhering to our target of achieving an EBIT margin of 15 percent by 2015."

Revenue by strategic business unit

Figures in
EUR '000
6 Months 2010/2011 6 Months 2011/2012 Change from prev. year
Ophthalmic Systems

173,367 184,781 6.6%

Surgical Ophthalmology

45,256 51,942 14.8%


157,421 195,075 23.9%

Revenue by region

Figures in
EUR '000
6 Months 2010/2011 6 Months 2011/2012 Change from prev. year

129,996 149,423 14.9%


124,024 144,083 16.2%

Asia/Pacific region

122,024 138,292 13.3%

Jann Gerrit Ohlendorf
Director Corporate Communications
Carl Zeiss Meditec AG
Phone: +49 3641 220-331

Henriette Meyer
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-106
Fax: +49 3641 220-117

Number: 0048-2012-ENG OP

Number of Words: 1098
Number of Characters: 11401

Go To Top
To overview